T1	p 205 249	patients with atrial fibrillation ( AF ) but
T2	p 691 783	44 countries ) trial of patients with nonvalvular AF and at least 1 risk factor for stroke .
T3	p 813 852	total of 18,113 patients . Patients who
T4	p 858 867	VKA-naive
T5	i 30 35	RE-LY
T6	i 73 107	anticoagulant therapy , warfarin ,
T7	i 117 165	with dabigatran . Vitamin K antagonists ( VKAs )
T8	i 273 293	Dabigatran etexilate
T9	i 299 306	prodrug
T10	i 363 385	inhibitor dabigatran .
T11	i 478 486	warfarin
T12	i 560 570	dabigatran
T13	i 616 621	RE-LY
T14	i 1430 1440	dabigatran
T15	o 943 1103	is stroke ( including hemorrhagic ) or systemic embolism . Safety outcomes are bleeding , liver function abnormalities , and other adverse events . Adjudication